Candel Therapeutics

Yahoo Finance • last month

Candel Therapeutics to Host Virtual R&D Event on December 5, 2025

NEEDHAM, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients f... Full story

Yahoo Finance • last month

Candel pausing development of CAN-2409 in prostate cancer type

[Prostate cancer with organs and tumor or cancerous cells 3D rendering illustration. Anatomy, oncology, biomedical, disease, medical, biology, science, healthcare concepts.] libre de droit/iStock via Getty Images * Candel Therapeutics (... Full story

Yahoo Finance • last month

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Presented new subgroup analyses from phase 3 clinical trial of CAN-2409 in localized prostate cancer at the American Society for Radiation Oncology (ASTRO) 2025 meeting, demonstrating improved prostate cancer-specific disease-free survival... Full story

Yahoo Finance • 2 months ago

Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London

NEEDHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients f... Full story

Yahoo Finance • 2 months ago

Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

NEEDHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients f... Full story

Yahoo Finance • 2 months ago

Candel Therapeutics signs $130M term loan facility with Trinity Capital

* Candel Therapeutics (NASDAQ:CADL [https://seekingalpha.com/symbol/CADL]) announced [https://seekingalpha.com/pr/20264571-candel-therapeutics-enters-into-130-million-term-loan-facility-with-trinity-capital-inc]on Tuesday that it has ent... Full story

Yahoo Finance • 2 months ago

Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.

$50 million drawn down at closing, with access to up to an additional $80 millionStrengthens Company’s financial position; enables initiation of phase 3 clinical trial of CAN-2409 in non-small cell lung cancer (NSCLC)Provides non-dilutive... Full story

Yahoo Finance • 2 months ago

Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine

NEEDHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients f... Full story

Yahoo Finance • 3 months ago

Candel Therapeutics to Present at the SITC 2025 Annual Meeting

NEEDHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients f... Full story

Yahoo Finance • 3 months ago

Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

CAN-2409 improved disease-free survival in patients with intermediate-to-high-risk, localized prostate cancer compared to placebo in patients treated with either conventional or moderate hypofractionated radiotherapy with curative intent,... Full story

Yahoo Finance • 3 months ago

Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

NEEDHAM, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients... Full story

Yahoo Finance • 4 months ago

Erasca, Candle, Xencor drop as BofA downgrades on lack of near-term catalysts

[Wall Street New York stock exchange stock market] alexsl Erasca (NASDAQ:ERAS [https://seekingalpha.com/symbol/ERAS]), Candel Therapeutics (NASDAQ:CADL [https://seekingalpha.com/symbol/CADL]), and Xencor (NASDAQ:XNCR [https://seekingalpha... Full story

Yahoo Finance • 4 months ago

Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board

NEEDHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients... Full story

Yahoo Finance • 4 months ago

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

NEEDHAM, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients f... Full story

Yahoo Finance • 4 months ago

Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Presented positive results from the phase 3 randomized, placebo-controlled clinical trial of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer, during an oral presentation at the 2025 Annual Meeting of the American Society o... Full story

Yahoo Finance • 5 months ago

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

NEEDHAM, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients f... Full story

Yahoo Finance • 5 months ago

Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer

NEEDHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients f... Full story

Yahoo Finance • 6 months ago

Brookline Capital initiates Candel Therapeutics stock with Buy rating, $25 target

Investing.com - Brookline Capital Markets initiated coverage on Candel Therapeutics Inc. (NASDAQ:CADL), currently trading at $6.09 with a market cap of $307M, with a Buy rating and a $25.00 price target. According to InvestingPro data, a... Full story

Yahoo Finance • 6 months ago

Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution

NEEDHAM, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients f... Full story

Yahoo Finance • 6 months ago

Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock

NEEDHAM, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients f... Full story